Skip to main content

Loading market data...

DNLI

Denali Therapeutics Inc.

NASDAQ • United states

$18.93

+$0.89

(+4.93%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Denali Therapeutics Inc. (DNLI)

Unavailable

Quotes may be delayed

$3.03B

Market Cap

1,823,224

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Denali Therapeutics Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

6 Aug 2026

Denali Therapeutics Inc. filed Form 10-Q

Denali Therapeutics Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

6 Aug 2026

Denali Therapeutics Inc. reported Operating or financial results

Denali Therapeutics Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

4 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Denali Therapeutics Inc..

28 Jul 2026

Denali Therapeutics Inc. reported An acquisition or sale of significant assets

Denali Therapeutics Inc. filed an 8-K covering an acquisition or sale of significant assets, supporting financial statements or exhibits.

8 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Denali Therapeutics Inc..

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$201.53M

Total assets (USD)$1.16B

Total liabilities (USD)$322.78M

Shareholders' equity (USD)$835.18M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$3.60M	−$130.54M	−$127.55M	−$0.68	10-Q · 6 Aug 2026
Q2 2025	$0	−$134.96M	−$124.12M	−$0.72	10-Q · 6 Aug 2026
Q4 2024	$0	−$129.85M	−$114.75M	Unavailable	10-K · 27 Feb 2025
Q3 2024	$0	−$123.19M	−$107.19M	−$0.63	10-Q · 6 Nov 2024
Q2 2024	$0	−$116.59M	−$99.03M	−$0.59	10-Q · 1 Aug 2024
Q1 2024	$0	−$117.72M	−$101.80M	−$0.68	10-Q · 7 May 2024

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $36.11

90.8% upside potential

📈

Strong Buy

Unavailable

👍

Buy

11

⏸️

Hold

0

📉

Sell

0

11 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 02:50 UTC Targets range 29.00–42.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

4

Sep 2026

Chin Peter Scott

Chief Medical Officer

Open-market sale

$22.29 per share

1,654 shares

2

Sep 2026

Thornberry Nancy

Director

Open-market sale

$22.90 per share

11,439 shares

1

Sep 2026

Schuth Alexander O.

COFO and Secretary

Open-market sale

$23.44 per share

2,768 shares

12

Aug 2026

Watts Ryan J.

Director, President and CEO

Gift

Unavailable per share

32,220 shares

11

Aug 2026

Schuth Alexander O.

COFO and Secretary

Open-market sale

$25.07 per share

2,857 shares

3

Jun 2026

FLATLEY JAY T

Director

Grant or award

Unavailable per share

6,408 shares

3

Jun 2026

Klein Peter S

Director

Grant or award

Unavailable per share

6,408 shares

3

Jun 2026

Krognes Steve E.

Director

Grant or award

Unavailable per share

6,408 shares

Top Shareholders

T. Rowe Price Investment Management, Inc.

16,178,963 shares

89.912% change

6/30/2026

Blackrock, Inc.

14,026,413 shares

7.61% change

6/30/2026

Vanguard Group Inc

13,057,890 shares

8.88% change

12/31/2025

Baillie Gifford & Co

11,960,230 shares

-0.881% change

6/30/2026

State Street Corp

7,049,304 shares

12.393% change

6/30/2026

Temasek Holdings (Private) Ltd

7,012,974 shares

0% change

6/30/2026

Vanguard Portfolio Management Llc

6,477,057 shares

5.831% change

6/30/2026

Vanguard Capital Management Llc

6,275,729 shares

2.078% change

6/30/2026

Fmr Llc

4,535,836 shares

-0.864% change

6/30/2026

Goldman Sachs Group Inc

4,155,895 shares

-5.703% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 02:51 UTC· 1 day ago

Research coverage and investment tools

Denali Therapeutics Inc. (DNLI) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$18.93 on 20 Oct 2026. That is 38% of the way from its 52-week low of US$13.75 to its 52-week high of US$27.30. Its market capitalisation was US$3.03 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$3.60M	−$130.54M	−$127.55M	−$0.68	—	-3,622.1%	−$97.81M	10-Q · 6 Aug 2026 (opens in a new tab)
Q2 2025	$0	−$134.96M	−$124.12M	−$0.72	—	—	−$79.58M	10-Q · 6 Aug 2026 (opens in a new tab)
Q4 2024	$0	−$129.85M	−$114.75M	Unavailable	—	—	−$88.81M	10-K · 27 Feb 2025 (opens in a new tab)
Q3 2024	$0	−$123.19M	−$107.19M	−$0.63	—	—	−$63.02M	10-Q · 6 Nov 2024 (opens in a new tab)
Q2 2024	$0	−$116.59M	−$99.03M	−$0.59	—	—	−$96.01M	10-Q · 1 Aug 2024 (opens in a new tab)
Q1 2024	$0	−$117.72M	−$101.80M	−$0.68	—	—	−$115.77M	10-Q · 7 May 2024 (opens in a new tab)

Cash and equivalents: $201.53M
Total assets: $1.16B
Total liabilities: $322.78M
Shareholders' equity: $835.18M

10-Q · 6 Aug 2026

Denali Therapeutics Inc. filed Form 10-Q (opens in a new tab)

Denali Therapeutics Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 6 Aug 2026

Denali Therapeutics Inc. reported Operating or financial results (opens in a new tab)

Denali Therapeutics Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G/A · 4 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Denali Therapeutics Inc..
8-K · 28 Jul 2026 · Merger or acquisition Completed

Denali Therapeutics Inc. reported An acquisition or sale of significant assets (opens in a new tab)

Denali Therapeutics Inc. filed an 8-K covering an acquisition or sale of significant assets, supporting financial statements or exhibits.
SCHEDULE 13G/A · 8 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Denali Therapeutics Inc..

Insider	Date	Transaction	Shares	Average price	Filing
Chin Peter Scott Chief Medical Officer	4 Sep 2026	Open-market sale (S)	−1,654	$22.29	Form 4 (opens in a new tab)
Thornberry Nancy Director	2 Sep 2026	Open-market sale (S)	−11,439	$22.90	Form 4 (opens in a new tab)
Schuth Alexander O. COFO and Secretary	1 Sep 2026	Open-market sale (S)	−2,768	$23.44	Form 4 (opens in a new tab)
Watts Ryan J. Director, President and CEO	12 Aug 2026	Gift (G)	−32,220	—	Form 4 (opens in a new tab)
Schuth Alexander O. COFO and Secretary	11 Aug 2026	Open-market sale (S)	−2,857	$25.07	Form 4 (opens in a new tab)
FLATLEY JAY T Director	3 Jun 2026	Grant or award (A)	+6,408	—	Form 4 (opens in a new tab)
Klein Peter S Director	3 Jun 2026	Grant or award (A)	+6,408	—	Form 4 (opens in a new tab)
Krognes Steve E. Director	3 Jun 2026	Grant or award (A)	+6,408	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
T. Rowe Price Investment Management, Inc.	6/30/2026	16,178,963	89.912%
Blackrock, Inc.	6/30/2026	14,026,413	7.61%
Vanguard Group Inc	12/31/2025	13,057,890	8.88%
Baillie Gifford & Co	6/30/2026	11,960,230	-0.881%
State Street Corp	6/30/2026	7,049,304	12.393%
Temasek Holdings (Private) Ltd	6/30/2026	7,012,974	0%
Vanguard Portfolio Management Llc	6/30/2026	6,477,057	5.831%
Vanguard Capital Management Llc	6/30/2026	6,275,729	2.078%
Fmr Llc	6/30/2026	4,535,836	-0.864%
Goldman Sachs Group Inc	6/30/2026	4,155,895	-5.703%

Previous close: 18.04 USD
Day range: 17.95 – 19.33 USD
52-week range: 13.75 – 27.30 USD
Volume: 1,823,224
Market cap: $3.03B
Average volume: 1,590,739
EPS (FY 2025, diluted): −2.97 USD
Shares outstanding: 159.85M
Beta (5Y monthly): 1.07

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:08 UTC· 2 hours ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for DNLI yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.